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In this review, we focus on lifestyle changes, especially dietary habits, that are at the basis of chronic systemic low grade inflammation, insulin resistance and
Western diseases. Our sensitivity to develop insulin resistance traces back to our rapid brain growth in the past 2.5 million years. An inflammatory reaction
jeopardizes the high glucose needs of our brain, causing various adaptations, including insulin resistance, functional reallocation of energy-rich nutrients and
changing serum lipoprotein composition. The latter aims at redistribution of lipids, modulation of the immune reaction, and active inhibition of reverse
cholesterol transport for damage repair. With the advent of the agricultural and industrial revolutions, we have introduced numerous false inflammatory triggers
in our lifestyle, driving us to a state of chronic systemic low grade inflammation that eventually leads to typically Western diseases via an evolutionary conserved
interaction between our immune system and metabolism. The underlying triggers are an abnormal dietary composition and microbial flora, insufficient physical
activity and sleep, chronic stress and environmental pollution. The disturbance of our inflammatory/anti-inflammatory balance is illustrated by dietary fatty
acids and antioxidants. The current decrease in years without chronic disease is rather due to “nurture” than “nature,” since less than 5% of the typically Western
diseases are primary attributable to genetic factors. Resolution of the conflict between environment and our ancient genome might be the only effective manner
for “healthy aging,” and to achieve this we might have to return to the lifestyle of the Paleolithic era as translated to the 21st century culture.
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Keywords: Chronic systemic low grade inflammation; Evolution; Brain; Encephalization quotient; Immune system; Diet; Fatty acids; Fish oil; Fruits; Vegetables;
Antioxidant network; Metabolic syndrome; Glucose; Homeostasis; Insulin resistance; Cholesterol; Lifestyle; Antioxidants; Resoleomics; Pro-inflammatory
nutrients; Anti-inflammatory nutrients1. Introduction
In recent years, it has become clear that chronic systemic low
grade inflammation is at the basis of many, if not all, typicallyWestern
diseases centered on the metabolic syndrome. The latter is the
combination of an excessive body weight, impaired glucose homeo-
stasis, hypertension and atherogenic dyslipidemia (the “deadly
quartet”), that constitutes a risk for diabetes mellitus type 2,
cardiovascular disease (CVD), certain cancers (breast, colorectal,
pancreas), neurodegenerative diseases (e.g., Alzheimer's disease),
pregnancy complications (gestational diabetes, preeclampsia), fertil-
ity problems (polycystic ovarian syndrome) and other diseases [1].
Systemic inflammation causes insulin resistance and a compensatory
hyperinsulinemia that strives to keep glucose homeostasis in balance.
Our glucose homeostasis ranks high in the hierarchy of energy
equilibrium, but becomes ultimately compromised under continuous⁎ Corresponding author. Clinical Chemist, Laboratory Medicine, Building,
Internal zip code EA61 University Medical Center Groningen (UMCG),
Hanzeplein, 1, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. Tel.:
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http://dx.doi.org/10.1016/j.jnutbio.2013.02.009
Open access under CC BY-NC-ND license.inflammatory conditions via glucotoxicity, lipotoxicity, or both,
leading to the development of beta-cell dysfunction and eventually
Type 2 diabetes mellitus [2].
Insulin resistance has a bad name. The ultimate aim of this survival
strategy is, however, deeply anchored in our evolution, during which
our brain has grown tremendously. The goal of reduced insulin
sensitivity is, among others, the reallocation of energy-rich nutrients
because of an activated immune system [3,4], limitation of the
immune response, and the repair of the inflicted damage. To that end,
serum lipoproteins adopt a pattern that bears resemblance with the
“hyperlipidemia of sepsis,” accompanied by seemingly inconsistent
changes in serum cholesterol, increased triglycerides, decreased high-
density lipoprotein (HDL) cholesterol, and an increase of “small
dense” low-density lipoprotein (LDL) particles, of which the latter
three constitute the triad of atherogenic dyslipidemia that is part of
the metabolic syndrome [5–10].
From the perspective of our brain growth during evolution, we
address the question of why Homo sapiens is so sensitive to the
development of insulin resistance. The purpose and the underlying
mechanisms leading to insulin resistance and the associated dyslipi-
demia are subsequently discussed in more detail. We argue that our
current Western lifestyle is the cause of many false inflammatory
Fig. 1. Evolution of our brain size within the past 3.5 million years. Our brain has grown fast since the Homo erectus (1.7-2.0 million years ago). The newborn Homo sapiens, the adult
chimpanzee and the Homo floresiensis [18] have brain volumes of around 400 ml.
Adapted from Aiello and Wheeler [19] with permission from The University of Chicago Press.
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grade inflammation, insulin resistance, the metabolic syndrome, and
eventually to the development of the above mentioned typically
Western diseases of affluence. To find a solution for the underlying
conflict between our environment and our ancient genome, we also
go back in time. With the reconstruction of our Paleolithic diet, we
might be able to obtain information on the nutritional balance that
was at the basis of our genome.We argue that insight into this balance
bears greater potential for healthy aging than the information from
the currently reigning paradigm of “evidence-based medicine” (EBM)
and “randomized controlled trials” (RCTs) with single nutrients.2. Our brain growth rendered us sensitive to glucose deficits
Homo sapiens and the current chimpanzees and bonobos share a
common ancestor, who lived in Africa around 6 million years ago.
Since about 2.5 million years ago, our brain has strongly grown from
an estimated volume of 400 ml to the current volume of approxi-
mately 1400 ml (Fig. 1). This growth was enabled by the finding of a
high-quality dietary source,1 that was easy to digest and contained an
ample amount of nutrients, necessary for the building and mainte-
nance of a larger brain. The nutritional quality of primate food
correlates positively with relative brain size and inversely with body
weight, suggesting that a larger brain requires a higher dietary quality
[11]. The necessary so-called “brain selective nutrients” include,
among others, iodine, selenium, iron, vitamins A and D, and the fish
oil fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), that jointly are abundantly available in the land-water eco-
system. There are compelling arguments that a sizeable part of our
evolution occurred at places where the land meets the water [12–15],
but also that we have changed our lifestyle in a too short period of
time. These changes started from the agricultural revolution (around
10,000 years ago) and became accelerated since the industrial1 Food quality refers to the energy content and/or the nutrient content of a diet.
An increase in food quality may derive from the consumption of a diet with
another composition or the modification of the diet by, e.g., cooking or genetic
manipulation [11].revolution (about 100–200 years ago). They created a conflict
between our current lifestyle, including our diet, and our ancient
genome, that, with an average effective mutation rate of 0.5% per
million years, still resides for the greater part in the Paleolithic era
[16,17]. It is not by chance that the above mentioned brain selective
nutrients are among those of which we currently exhibit the largest
deficits worldwide. These deficits are masked by enrichment and
fortification of our current diet with iodine (in salt), vitamins A and D
(e.g., in margarines and milk) and iron (flour, cereals).
Our brain consumes 20–25%2 of our basal metabolism [11–17,20]
and is thereby together with the liver (19%2), our gastrointestinal
tract (15%2), and skeletal musculature (15%2) among the quantita-
tively most important organs in energy consumption [19]. The infant
brain consumes as much as 74% of the basal metabolism [11,21]. In
contrast to most other organs, the brain uses mostly glucose as an
energy source. There is no other primate equipped with such a large,
glucose-consuming, luxury organ as our brain. For example, our
closest relative, the chimpanzee, has a brain volume of 400 ml, which
consumes about 8–9% of the basal metabolism. Because of the high
energy expenditure of a large brain, it was necessary to make various
adjustments in the sizes of some other organs. There is a linear
relationship between body weight and basal metabolism among
terrestrial mammals (Fig. 2). This apparently dogmatic relationship
predicts that, due to the growth of our brain, other organs with high
energy consumption had to be reduced in size, what in evolution is
known as a “trade-off”.3 As a consequence of this “expensive tissue
hypothesis” of Aiello and Wheeler [19], our intestines, amongst
others, had to become reduced in size. However, this exchange of
expensive tissue probably occurred prior to, or simultaneous with,
our brain growth, in which the trigger was the consumption of the
easily digestible high-quality food [20] that contains the above-
mentioned “brain selective nutrients” from the land-water ecosys-
tem. Under these “conditions of existence” (Darwin), a single
mutation in a growth regulatory gene is likely to have been sufficient
for the brain to grow. This notion derives from the existence of
genetically-determinedmicro- [22] andmacrocephaly [23] and it is as2 These estimates derive from various publications and therefore do not add to
100%. They should be regarded as indications.
3 The beneficial exchange of a certain property into another one.
Fig. 2. Relationship between body weight and basal metabolism in 51 land mammals
(20 non-primates, 30 primates, and humans). RMR, resting metabolic rate.
Adapted from Leonard et al. [11] with permission from Elsevier.
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lengths of Darwins” legendary Galapagos finches [24–26]. Compared
with our close (vegetarian) relatives in the primate world, we possess
a relatively long small intestine and a relatively short large intestine,
which corresponds with the digestion of high quality food (such as
meat and fish) in the small intestine, and the lesser need of a long
colon for the digestion of complex carbohydrates (e.g., fiber) from a
typically vegetarian diet [19]. Unlike our near primates, such as the
gorilla, our teeth and the attachments of our jaw muscles are not
specialized for the processing of tough vegetarian food. Also our
muscle mass became adapted, since its current size is relatively small
compared to our body weight. For instance, when compared with the
chimpanzee, we are definitely weak. On the other hand, we have a
relatively sizeable fat mass, which probably serves as a guarantee for
the high energy requirement of our brain.
Our brain's energy consumption is quite stable. Unlike other
organs, the energy consumption of the brain can not be down-
regulated at times of a negative energy balance or fasting [11,20]. Our
brain also gets spared during prolonged fasting, while other organs
such as the liver, spleen, kidneys and even the heart, are sacrificed for
energy generation [27]. This hierarchy also applies to the prenatal
brain, whose development is conserved during intrauterine growth
restriction [28]. An example is the Indian “thin fat baby,” with a birth
weight of 2700 g. Compared with its 3,500 g counterpart from the UK,
this infant has a similar brain size and a relatively large fat
compartment, at the expense of the somatic growth of the skeletal
muscle, kidneys, liver and the pancreas [28]. Our brain ranks high in
the functional hierarchy and should be provided with the necessary
energy at all times.
Apart from its large size, there is nothing special about our brain
within the primate world. Compared with other species, primates
have a very economical space-saving brain, but among the primates,
brain weight correlates with the number of neurons [29–32] and
intelligence [33]. Actually, our brain is no more than an oversized
primate brain [29]. What does distinguish us from other species is the
high ratio between our brain size and our body weight, which is also
named encephalization quotient (EQ) (Fig. 3). Toothed whales (brain
weight 9000 g) and African elephants (4200 g) have much largerbrains than humans, but they have lower EQs [34]. Among the
primates, EQ does not correlate with intelligence [33]. Our high EQ
has major implications for our energy management, particularly at
times of “glucose shortage”. Under normal circumstances, our brain
functions almost entirely on glucose, consuming up to 130 g/day [27].
Compared with the apparently unlimited storage capacity for fat, we
only dispose of a small reserve of glucose that is stored as glycogen in
the liver (up to 100–120 g; mobilizable) and muscles (360 g; for local
usage), while some glycogen can even be found in brain's astrocytes
[35]. With the exception of the glycerol moiety, we can not convert fat
into glucose. The reduced carbohydrate intake that came along during
evolution with the transition from vegetarians to omnivores rendered
us strongly dependent on gluconeogenesis from (glucogenic) amino
acids. This was possible because we simultaneously consumed more
protein frommeat and fish, which is also referred to as the “carnivore
connection” [36]. After the depletion of our glycogen reserves, for
instance after an overnight fast, we obtain the necessary glucose for
our brain via gluconeogenesis from glycerol and amino acids. Under
normal conditions, these amino acids derive from our dietary proteins
after a meal, but during starvation, they become extracted from our
tissues by catabolism of functional proteins, at the expense of our lean
body mass. Under such circumstances of severe glucose deficit, the
energetic need of our brain becomes increasingly covered by ketone
bodies from fat [37,38].
A glucose deficit leads to competition between organs for the
available glucose. As previously mentioned, this occurs during
fasting, but also during pregnancy and infection/inflammation.
Fasting is characterized by a generalized shortage of glucose (and
other macronutrients), but in case of pregnancy and inflammation
we deal with active compartments competing with the brain for the
available glucose, i.e., the growing child and the activated immune
system, respectively. During competition between organs for
glucose, we fulfill the high glucose needs of the brain by a
reallocation of the energy-rich nutrients, and to that end, we need
to become insulin resistant.
3. Reallocation of energy-rich nutrients by insulin resistance
The developing child grows fast in the third trimester of
pregnancy. In this period, the supply of the necessary building blocks
like glucose and fatty acids should be independent of the maternal
metabolic status, which is known as the state of “accelerated
starvation” and “facilitated anabolism” [38]. Glucose crosses the
placenta without restriction. Fetal needs are directive, since the
developing fetus is high in the evolutionary hierarchy. If necessary,
the fetal needs become covered at the expense of themother, which is
known as the “depletion syndrome”.
During infection/inflammation we deal with the metabolic needs
of an activated immune system for acute survival. The inactive
immune system consumes about 23%2 of our basal metabolism, of
which as much as 69% derives from glucose (47%) and the glycogenic
amino acid glutamine (22%). Upon activation, the energy requirement
of our immune system may increase with about 9–30% of our basal
metabolic rate. In multiple fractures, sepsis and extensive burns, we
deal with increases up to 15–30, 50, and 100% of our basal
metabolism, respectively [3,4,39].
The way we save glucose for our brain during starvation, for the
brain and the fetus during pregnancy, and for the brain and immune
system during infection/inflammation, is by causing insulin resistance
in selected insulin-dependent tissues. These tissues are thereby
forced to switch to the burning of fat. Due to insulin resistance, the
adipose tissue compartment will be encouraged to distribute free
fatty acids, while the liver will be encouraged to produce glucose via
gluconeogenesis and to distribute triglycerides via very low-density
lipoprotein (VLDL). The aforementioned (asymmetric) “thin fat baby”
Fig. 3. Encephalization quotient of selected mammals. The EQ has been normalized with the cat as a reference.
Data adapted from Roth and Dicke [34].
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the growth restricted body (islets of Langerhans included), has
relatively high cord plasma insulin and glucose concentrations at
birth [28]. These characteristics of insulin resistance and diabetes
mellitus are probably necessary for the postpartum, saving of as much
as possible of the available glucose for the brain, whereas the other
organs are provided with fatty acids from the sizeable adipose tissue
stores. This intrauterine 'programming', that follows the prediction of
a thrifty postnatal life comes along with health risks, notably when
the prediction proves false [40,41]. According to the “Barker
hypothesis,” at adult age, these children have a higher chance of
diseases related to the metabolic syndrome, especially when they are
raised in our current obesogenic society. The unfavorable interaction
of their high EQ with a high body weight is already demonstrable at
the age of 8 years [42]. Essentially, their postnatal risk is attributable
to a (probably epigenetic) “intrauterine programming,” that traces
back to the high hierarchical ranking of our brain in both growth and
energy needs, also referred to as “the selfish brain” [43].
Glucose intolerance [26] and insulin resistance have been reported
in calorie restriction, extreme fasting and anorexia nervosa, and may
even cause, under these circumstances, diabetes mellitus type 2,
notably in those subjects sensitive to its development [44]. According
to textbooks, insulin resistance during the third trimester of
pregnancy is caused by the hormonal environment, among which
HPL, progesterone, estrogens, prolactin and cortisol are mentioned.
However, placental tumor necrosis factor alpha (TNFα) correlates
best with measures of maternal insulin resistance [45,46]. Pregnancy
is therefore sometimes referred to as a physiological state of systemic
low grade inflammation [47]. As a consequence of reduced insulin
sensitivity, maternal circulating concentrations of energy-rich nutri-
ents, such as glucose and fat, tend to increase, promoting their
transport across the placenta. Under non-pregnant conditions, this
situation would resemble pathology, but is tolerable during the 9
months of a pregnancy, while the largest changes occur during the
third trimester.During infection and inflammation, the signals for metabolic
adaptation become transmitted by pro-inflammatory cytokines. The
resulting insulin resistance causes reallocation of energy (i.e. the aim
of the process; see above), which illustrates that inflammation and
metabolism are highly integrated [49–51]. At the molecular level, the
interaction takes place through the influences of the nuclear factor
kappa B (NFκB) and the AP-1 Fos/June inflammatory pathways on the
PI3K/Akt signal transduction pathway for nutrient metabolism and
the Ras/MAPK pathway for gene expression, which are both part of
the insulin signal transduction [48,52]. To put it simply: the activated
inflammatory signal transduction pathway causes inhibition of the
postreceptor insulin signaling pathway, which becomes noticeable by
what we know as insulin resistance (Fig. 4). Insulin resistance
especially refers to a grossly diminished reduction of the circulating
glucose concentration by insulin. However, insulin has many
functions, and thereby exerts different effects in the various organs
carrying the insulin receptor. Consequently, the “resistance” affects
the many insulin signal transduction pathways at various degrees,
and thereby works out differently with respect to the various insulin
functions [1,53]. Some processes are impaired (i.e., are genuinely
“resistant”), while others remain intact and become excessively
stimulated by the compensatory hyperinsulinemia. This compensa-
tory increase of the circulating insulin levels aims at the prevention of
a disturbed glucose homeostasis and thereby the onset of type 2
diabetes mellitus. The persistence of compensatory hyperinsulinism
is responsible for most, if not all, of the abnormalities that belong to
the metabolic syndrome [1].
In muscle and fat cells, insulin resistance induces a diminished
glucose uptake and therefore a reduced storage of glucose as glycogen
and triglycerides. In fat cells, it causes decreased uptake of circulating
lipids, increased hydrolysis of stored triglycerides and their mobili-
zation as free fatty acids and glycerol. In liver cells, insulin resistance
induces the inability to suppress glucose production and secretion, in
addition to decreased glycogen synthesis and storage. The hereby
promoted reallocation of energy-rich substrates (glucose to the brain,
Fig. 4. Mechanistic connection between inflammation and insulin resistance. The NFκB and AP-1 Fos/June inflammatory pathways inhibit the PI3K/AKT signal transduction pathway for
nutrient metabolism and the Ras/MAPK pathway for gene expression, both part of the insulin signaling. CAP, Cbl associated protein; Cbl, Proto-oncogene product; ER, endoplasmic
reticulum; FFAs, free fatty acids; Gqα/11, heterotrimeric G protein; Ikkb, I kappa B kinase Beta; IRS, insulin receptor substrate; JNK, C-jun N-terminal kinase; NFkB, nuclear factor kappa
B; NO, nitric oxide; Ras/MAPK; PI3K, phosphatidylinositol 3-kinase; Ras-mitogen activated protein kinase; Shc, Src homology 2 containing protein; SOCS, supressor of cytokine
signaling; TLRs, Toll-like receptors.
Adapted from de Luca and Olefsky [48] with permission from Elsevier.
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insulin resistant) and the compensatory hyperinsulinemia, are meant
for short-term survival, and their persistence as a chronic state are at
the basis of the ultimate changes that we recognize as the symptoms
of the metabolic syndrome, including the changes in glucose and lipid
homeostasis [3,4] and the increasing blood pressure. For example, the
concomitant hypertension has been explained by a disbalance
between the effects of insulin on renal sodium reabsorption and
NO-mediated vasodilatation, in which the latter effect, but not the
first, becomes compromised by insulin resistance, causing salt
sensitivity and hypertension [54].
Reaven coined the term “metabolic syndrome” and subsequently
renamed it the “insulin resistance syndrome” [1]. However, it
becomes increasingly clear that we could better refer to it as the
“chronic systemic low-grade inflammation induced energy realloca-
tion syndrome”. The reason for this broader name derives from the
recognition that insulin resistance is only part of the many
simultaneously occurring adaptations. To their currently known
extent, these adaptations and consequences are composed of: (i)
reduced insulin sensitivity (glucose and lipid redistribution, hyper-
tension), (ii) increased sympathetic nervous system activity (stimu-
lation of lipolysis, gluconeogenesis and glycogenolysis), (iii)
increased activity of the HPA-axis [hypothalamus-pituitary-adrenal
gland (stress) axis, mild cortisol increase, gluconeogenesis, with
cortisol resistance in the immune system], (iv) decreased activity of
the HPG-axis (hypothalamus-pituitary-gonadal gland axis; decreased
androgens for gluconeogenesis from muscle proteins, sarcopenia,
androgen/estrogen disbalance, inhibition of sexual activity and
reproduction), (v) IGF-1 resistance (insulin-like growth factor-1; noinvestment in growth) and vi) the occurrence of “sickness behavior”
(energy-saving, sleep, anorexia, minimal activity of muscles, brain,
and gut) [3].
The HPT-axis (hypothalamic-pituitary-thyroid axis) has a central
role in our energy management. The adaptation of thyroid function in
subjects with the metabolic syndrome is yet unclear, possibly due to
the many concerted changes, such as an altered thyroid hormone
binding capacity, tissue uptake, conversion of T4 into T3, and tissue-
specific receptor expression and function. For example, T4 may
become converted into the highly active T3 within the target cell and
thereby, without visible changes of circulating hormone concentra-
tions, bind to the intracellular thyroid hormone receptor [55].
Whether intracellular T4 is converted into T3 or the inactive reverse
T3 (rT3), or is used as a source of iodine to kill bacteria, depends on
several factors, including cytokines, that determine the expression
pattern of the three involved deiodinases [55–57]. In euthyroid
subjects, free T4 (FT4) is associated with insulin resistance, inversely
related to total- and LDL-cholesterol, while also a positive relationship
between thyroid-stimulating hormone (TSH) and triglycerides has
been documented [58]. The reported changes during metabolic
syndrome [59], low-grade inflammation and insulin resistance [60]
are inconsistent, but do bear great resemblance with subclinical
hypothyroidism, with high-normal or slightly elevated TSH, and
normal FT4 concentrations [61,62]. Insulin resistance has recently
been associated with an increased T3/rT3 ratio, which is a measure of
peripheral thyroid hormone metabolism and suggests increased
thyroid hormone activity [63]. In contrast, during fasting, energy
expenditure becomes down-regulated, resulting in a normal or
decreased TSH and decreased serum thyroid hormone concentrations
Fig. 5. Changes in reverse cholesterol transport during the acute phase response.
Lipopolysaccharides (LPS) and cytokines reduce the ABCA1 (ATP-binding cassette
transporter A1) and the cholesterol efflux from peripheral cells to HDL. LPS reduces the
activities of various proteins involved in HDL metabolism, such as lecithin-cholesterol
acyltransferarse (LCAT), cholesterol ester transfer protein (CETP) and hepatic lipase
(HL). LPS and cytokines also down-regulate hepatic scavenger receptor class B type 1
(SRB1), resulting in a decreased cholesterol ester (CE) uptake in the liver. FC, free
cholesterol; LDL-R, LDL receptor; LRP, LDL receptor-related protein; PLTP, phospholipid
transfer protein.
Adapted from Khovidhunkit et al.[66] with permission from The American Society for
Biochemistry and Molecular Biology.
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TSH, and an increase of rT3 (and thus a decrease of the T3/rT3 ratio)
occurs progressively with the severity of the “non-thyroidal illness
syndrome” (also called the “Low T3 syndrome” and “euthyroid sick
syndrome”) [55] which is explained as an adaptation of the body to
prevent excessive (protein) catabolism as part of the acute phase
response [56].
All of the above mentioned adaptations of our metabolism are
associated with changes in the serum lipoprotein profile, which are
part of the metabolic syndrome. The purpose of these changes will be
explored in more detail below.
4. Changes in serum lipoproteins
The quantitative and qualitative changes in the composition of
serum lipoproteins resulting from an inflammatory trigger have, in
addition to the reallocation of energy-rich nutrients (fatty acids to the
insulin resistant organs), at least two other goals [5–10,65]. These are:
(i) the modulation of the immune response by which we protect
ourselves from the harmful effects of invading bacteria, viruses and
parasites, and (ii) the restoration of the hereby inflicted damage.
However, if the subsequent changes in structure and function of
lipoproteins persist, they contribute to the development of athero-
sclerosis [66]. These long-term complications have not exerted
selection pressure during evolution and, consequently, no solution
has come into existence via the habitual process of spontaneous
mutation and natural selection.
The inflammatory trigger during an infection with Gram-negative
bacteria is initiated by lipopolysaccharides (LPS). Circulating lipopro-
teins aid in the clearance of this LPS. Hence, lipoproteins do not only
have functions in transporting lipids to and from tissues, but also play
important roles in limiting the inflammatory response [67]. The
ability of lipoproteins to bind LPS is proportional to the cholesterol
content of the lipoprotein [68], but the phospholipids/cholesterol
ratio of the lipoprotein is the principal determinant of the LPS-
binding capacity [69]. The available phospholipid surface is thus of
special importance and is, under normal circumstances, the largest for
the circulating HDL. However, critically ill patients exhibit decreases
of both esterified cholesterol and HDL (see below) and in those
patients, LPS is mainly taken up in the phospholipid layers of LDL
and VLDL. Binding of LPS to lipoproteins prevents activation of
LPS-responsive cells and encourages LPS clearance via the liver to the
bile. In line with this mechanism, it has been observed that a decrease
in plasma lipoproteins in experimental models increases LPS-induced
lethality [69].
The protective role of LDL is already known for some time, and this
process has probably been exploited during evolution. Currently,
there are over a thousand LDL-receptor mutations, many of which
lead to a reduced or absent hepatic uptake of LDL particles, and
consequently, to an elevated serum LDL-cholesterol [70]. The carriers
of these mutations have “familial hypercholesterolemia” (FH;
incidence about 1/400 in The Netherlands) or “defective apo-B100,”
if the mutation is located in the LDL-receptor ligand. They constitute
autosomal dominant disorders with a high risk of premature
atherosclerosis and mortality from CVD [71]. The arising question is
why evolution has preserved so many apparently detrimental
mutations in the LDL-receptor. Research with data from the
population registry office in The Netherlands showed that subjects
with FH lived longer until 1800, which turned into a shorter lifespan
than the general population after 1800 [72]. Important support for an
explanation came from studies with LDL-receptor knockout mice, and
also with transgenic mice overexpressing apo-A1, the structural
protein of HDL. These mutants have a high LDL- and HDL-cholesterol,
respectively, are resistant to LPS-induced mortality, and have better
survival of severe Gram-negative infection compared with the wildtype [66,73]. In other words, FH might have become widespread
during evolution due to the modulating effect of a high LDL (i.e., “a
high cholesterol”) during Gram-negative infections, that were much
more common in the past. This benefit might have become a risk
following the introduction of a typically Western lifestyle (see
below), to which subjects with FH seem particularly sensitive [72].
As mentioned above, among the lipoproteins, notably HDL has the
capacity to bind LPS and thereby to prevent an LPS-induced activation
of monocytes and the subsequent secretion of proinflammatory
cytokines [5]. However, during the “lipidemia of sepsis,” the HDL
concentration decreases while also the HDL particles decrease in size
[6]. Their function changes as part of the acute phase response: the
immunomodulatory properties vanish to a high extent and HDL even
becomes proinflammatory. The apo-A1 and cholesterol esters are lost
from the HDL particle, the activities of HDL-associated enzymes and
exchange proteins decrease, and these proteins are, among others,
replaced by serum amyloid A (SAA) [5,6]. Like C-reactive protein, SAA
is produced in the liver as part of the acute phase response. SAA is 90%
located in HDL, prevents the uptake of cholesterol by the liver and
directs it to other cells such as macrophages [8,66]. Both the
decreasing HDL-cholesterol and the concomitantly reduced “choles-
terol reverse transport,” promote the accumulation of cholesterol in
the tissues, where it is needed for the synthesis of steroid hormones
(e.g., cortisol) in the adrenal glands, the immune system and for the
synthesis of cellular membranes that became damaged by the
infection [66]. Also, the formation of small dense LDL [74] might be
functional because these particles are poorly cleared by the LDL-
receptor, easily penetrate the subendothelial space and by their
binding to the subendothelial matrix, take their cholesterol cargo to
the sites of damage in a highly efficient manner. It appears that there
are numerous mechanisms that jointly cause the active inhibition of
the reverse cholesterol transport in response to an acute phase
response (Fig. 5) [66,75].
Summarizing thus far, we humans are extremely sensitive to
glucose deficits, because our large brain functions mainly on glucose.
During starvation, pregnancy and infection/inflammation, we become
insulin resistant, along with many other adaptations. The goal is the
reallocation of energy-rich substrates to spare glucose for the brain,
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and our activated immune system that also functions mainly on
glucose. Under these conditions, the insulin resistant tissues are
supplied with fatty acids. Other goals of the changes in the serum
lipoprotein composition are their role in the modulation of the
immune response by the clearance of LPS during infection/inflam-
mation and the redirection of cholesterol to tissues for local damage
repair. The metabolic adaptations caused by inflammation illustrate
the intimate relationship between our immune system and metab-
olism. This relation is designed for the short term. In a chronic state it
eventually causes the metabolic syndrome and its sequelae. We are
ourselves the cause of the chronicity. Our current Western lifestyle
contains many false inflammatory triggers and is also characterized
by a lack of inflammation suppressing factors. These will be described
in more detail below.
5. Lifestyle-induced chronic systemic low grade inflammation
An inflammatory reaction is the reflection of an activated immune
system that aims to protect us from invading pathogens or reacts to a
sterile infection. If an activated immune system is uncontrolled, the
resulting secondary reactions have the ability to kill us. Rogers [76]
expresses it as follows: “…inflammation may be useful when
controlled, but deadly when it is not. For example, head trauma
may kill hundreds of thousands of neurons, but the secondary
inflammatory response to head traumamay kill millions of neurons or
the patient”. It is clear that an inflammatory reaction that has started
should subsequently be ended.
There are many factors in our currentWestern lifestyle that jointly
cause a state of chronic systemic low grade inflammation, which in
turn leads to chronically compromised insulin sensitivity, compen-
satory hyperinsulinemia and, eventually, the diseases related to the
metabolic syndrome. Lifestyle factors that cause inflammation can be
subdivided into an unbalanced composition of the diet (usually
referred to as “malnutrition”) [78–80] and non-food related factors
[77], which partly exert their influence via obesity [81] (Table 1).
Among the pro-inflammatory factors in our current diet, we find: the
consumption of saturated fatty acids [82] and industrially produced
trans fatty acids [83,84], a high ω6/ω3 fatty acid ratio [85–87], a low
intake of long-chain polyunsaturated fatty acids (LCP) of theω3 series
(LCPω3) from fish [88,89], a low status of vitamin D [90–92], vitamin
K [93] and magnesium [94–96], the “endotoxemia” of a high-fat low-
fiber diet [97,98], the consumption of carbohydrates with a high
glycemic index and a diet with a high glycemic load [99,100], a
disbalance between the many micronutrients that make up our
antioxidant/pro-oxidant network [101–103], and a low intake of fruit
and vegetables [103,104]. The “dietary inflammation index” of the
University of North Carolina is composed of 42 anti- and proin-
flammatory food products and nutrients. In this index, a magnesium
deficit scores high in the list of pro-inflammatory stimuli [105].
Magnesium has many functions, some of them, not surprisingly,
related to our energy metabolism and immune system, e.g., it is the
cation most intimately connected to ATP [95]. Indirect diet-related
factors are an abnormal composition of the bacterial flora in the
mouth [106], gut [106,107], and gingivae [108–110]. Chronic stress
[111,112], (passive) smoking and environmental pollution [77],
insufficient physical activity [113–118] and insufficient sleep
[119–123] are also involved.
All of the above listed lifestyle factors exhibit interaction and are
therefore difficult to study in isolation. As an example, the bacterial
flora may change secondary to the composition of our diet. An
inflammatory reaction might be at the basis of the observed relation
between the abnormal bacterial species in both our oral cavity and
intestine and our serum HDL- and LDL-cholesterol [106]. Saturated
fats may cause an inflammatory reaction especially when they arecombined with a carbohydrate-rich diet, notably carbohydrates with
a high glycemic index, and especially in subjects with the insulin
resistance syndrome [124–128].
6. Mechanisms of lifestyle-induced inflammation
Diets high in refined starches, sugar, saturated and trans fats, and
low in LCPω3, natural antioxidants, and fiber from fruits and
vegetables, have been shown to promote inflammation [82–84,129–
131] (Table 1). As most chronic (inflammatory) diseases have been
linked to diet, modifying it could prevent, delay or even heal these
diseases. Obviously, inflammation is an essential process for survival,
but our immune system should be carefully controlled to limit the
unavoidably associated collateral damage [132]. For instance, wound
healing and other immune challenges become controlled in our body
by a process coined by Serhan et al. [133–135] as resoleomics, using
metabolites produced from the LCP arachidonic acid (AA), EPA and
DHA [85,133–136]. However, our inflammatory and resolution genes
operate nowadays in a completely different environment than the
one to which they became adapted through mutation and natural
selection. In most (if not all) chronic diseases typical of Western
societies, the inflammatory response is not concluded because of
suboptimal or supramaximal responses [137,138].
It has been estimated that 10% of all deaths in the Netherlands are
attributable to unfavorable dietary composition and 5% to overweight.
In this scenario, the major contributors to diet-associated death were
insufficient intakes of fish, vegetables and fruits, with less important
roles for too high intakes of saturated and trans fatty acids [139]. The
consumption of fish, fruit and vegetables is considered too low in
most Western countries [139–143]. In the USA, low dietary ω3 fatty
acids and high dietary trans fatty acids may have accounted for up to
84,000 and 82,000 deaths, respectively, in 2005, while a low intake of
fruit and vegetables might have been responsible for 58,000 deaths
[144]. The Dutch [145] and the American Heart Association (AHA)
[146] dietary guidelines recommend to consume at least two servings
of fish per week (particularly fatty fish), but in 1998, the average fish
consumption in The Netherlands amounted to hardly 3 times per
month [139]. Only about 7% of the 9–13 year-old Dutch children eat
fish twice or more per week and 10% never eat fish [147]. In the USA,
the estimated intake of fish in 2007 was about 0.7 kg per month, per
person. More preoccupying is the fact that the USA is considered the
third largest consumer of seafood in the world [148,149]. Despite
improvements of the fatty acid contents of food products, only 5% of
the Dutch population follows a diet with the recommended fatty acid
pattern [139]. Eating fish once weekly was associated with a 15%
lower risk of CVD death compared with a consumption of less than
once per month [150], while each 20 g/day increase in fish
consumption was related to a 7% lower risk of CVD mortality [151].
The current Dutch recommendation for adults is 200 g fruits and
200 g vegetables per day [139], while in the USA, 4–5 servings of fruits
and 4–5 servings of vegetables are recommended in a 2,000 kcal diet
[152]. Between 1988 and 1998, the consumption of fruit and
vegetables in The Netherlands declined by 15–20%, and currently,
less than 25% of the Dutch population follows the recommendations
regarding the consumption of fruit, vegetables and dietary fiber [139].
As an example, currently 99% and 95% of the 9–13-year-old Dutch do
not adhere to the advice of consuming 150 g/day vegetables and 200
g/day fruits, respectively [147]. Meta analyses of prospective studies
indicated that b3 vs. N5 servings of fruits and vegetable per day
correspond with a 17% reduction in coronary heart disease [153] and
26% reduction in stroke [154], while the relation of low intakes with
mouth, pharynx, esophagus, lung, stomach, colon and rectum cancer
is considered substantially convincing [155].
In view of the numerous nutrients present in our food and their
many mechanisms of action in the inflammatory response, we
Table 1
Environmental factors that may cause chronic systemic low grade inflammation
Pro-inflammatory Anti-inflammatory
Lifestyle Exercise Too little (inactivity) Lifestyle Exercise/physical activity/fitness
Too much
Nutrition Alcohol (excessive) Nutrition Alcohol
Excessive energy intake Energy intake (restricted)
Starvation
'Fast food'/Western style diet Mediterranean diet
Fat High-fat diet Fat Fish/fish oil
Saturated fats Mono-unsaturated fats
Trans fatty acids Olive oil
High ω6/ω3 ratio Low ω6/ω3 ratio
Fiber (low intake) Fiber (high intake)
Fructose Nuts
Glucose High glucose/GI foods Low Gl foods
Glycemic load Grapes/raisins
Glycemic status Dairy calcium
Sugar-sweetened drinks Eggs










Weight gain Weight loss
Smoking Smoking cessation










Adapted from Egger and Dixon [77].
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EPA and DHA), and the antioxidants in fruit and vegetables, to
illustrate the many dietary components involved in our pro-
inflammatory/anti-inflammatory balance. However, before embark-
ing into these nutrient classes, it should be emphasized that our food
is in reality composed of biological systems, such as meat, fish,
vegetables and fruits, in which nutrients obey to the balance that
comes along with living material. Therefore, focusing on specific,
presently known mechanisms without sufficient knowledge of the
many possible interactions between the numerous nutrients in our
food should be regarded as a serious limitation. This is a reductionist
approach, whereas system dynamics and holistic approximations
would be more appropriate.
6.1. Fatty acids and inflammation
The media are consistently reporting on advises to reduce fat
consumption to avoid risks associatedwith obesity, CVD, diabetes and
other chronic diseases and conditions. Among the macronutrients, fat
does indeed contain the highest amount of energy per gram.
However, from a thermodynamic point of view, a “calorie is a calorie”
[156], implying that any macronutrient consumed in disbalance with
energy expenditure and thermogenesis might cause obesity. A recent
in-depth study revealed that “a calorie is not a calorie” in a metabolic
sense, showing that isocaloric diets with different macronutrient
compositions have different effects on resting and total energy
expenditure with decreasing energy expenditures in the sequencelow-fat dietblow-glycemic dietbvery low-carbohydrate diet [157],
and thereby suggesting that the diet with the highest protein and fat
content gives rise to the lowest weight gain. However, whether the
intake of fat per se and, as a matter of fact, any isolated nutrient [158],
can be held responsible for the epidemics of obesity, remains
controversial and counter intuitive [159–161]. Moreover, it is
becoming increasingly clear that about 10–25% of obese subjects
have little CVD and type 2 diabetes mellitus risk (a condition coined
“healthy obesity”) [162,163], that lean physically unfit subjects have
higher risk of CVD mortality than obese, but fit, subjects [164], and
that it is the quality and not the quantity of fat that conveys a major
health hazard [165]. The type of dietary fat affects vital functions of
the cell and its ability to resist dysfunction, e.g., by influencing the
interaction with receptors, by determining basic membrane charac-
teristics and by producing highly active lipid mediators [166,167].
Saturated fat intake has been associated with inflammation
[168,169]. However, the widely promoted reduction of saturated
fatty acids is increasingly criticized [170] and also the AHA advisory to
replace saturated fatty acids in favor of linoleic acid (LA) to 5–10 en%
[171]. Insufficient intake of particular fatty acids is, on the other hand,
likely to contribute to health hazards, including increased risk of
infection [172], dysregulated chronobiological activity and impaired
cognitive and sensory functions (especially in infants) [173]. Among
these important fatty acids are the LCPω3 derived from fish, of which
EPA and DHA are the most important members. In 2003, the intake of
EPA+DHA by adults in The Netherlands amounted to approximately
90mg/day (women 84mg/day andmen 103mg/day) [174], while the
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on an optimal effect in preventing CVD (anti-arrhythmic effect), but
there is good evidence that higher intakes may convey additional
favorable effects because of their anti-thrombotic properties and their
ability to reduce blood pressure, heart rate and triglyceride levels
[131]. It was calculated that our Paleolithic ancestors living in the
water-land ecosystem had daily intakes of 6–14 g EPA+DHA [176],
which correspond with the intakes by traditionally living Greenland
Eskimos [177], who, because of their low incidence of CVD, were at
the basis of the research on the beneficial effects of fish oil that started
in the 70s [178–180].
Both EPA and DHAmust be in balance with AA, which is the major
LCPω6 derived from meat, poultry, eggs [181–183] and also lean fish
[184,185]. Each of these LCPs may be synthesized by desaturation,
chain elongation and chain shortening from the parent “essential fatty
acids” LA (converted to AA) and alpha-linolenic acid (ALA) (con-
verted to EPA and DHA) [186], even though the production of EPA,
and notably DHA, occurs with difficulty in humans [187]. Included
among the symptoms of LA, LCPω3 and LCPω6 deficiencies are
fatigue, dermatological problems, immune problems, weakness,
gastrointestinal disorders, heart and circulatory problems, growth
retardation, development or aggravation of breast and prostate
cancer, rheumatoid arthritis, asthma, preeclampsia, depression,
schizophrenia, and attention deficit hyperactivity disorder
[173,188–190].
LCPω3 are implicated in many diseases and conditions, including
CVD, psychiatric diseases, pregnancy complications and suboptimal
(neuro) development [86,191–196]. Moreover, a growing number of
studies indicate the protective effects of dietary LCPω3 on mood
symptoms, cognitive decline, depression [197,198], Alzheimer's
disease [199] and, more generally, impaired quality of life both in
the elderly [200,201] and younger [202] populations. LCPω3 are
involved in numerous processes including energy generation, growth,
cell division, transfer of oxygen from the air to the bloodstream,
hemoglobin synthesis, normal nerve impulse transmission and brain
function. Many differentmechanisms are operational: LCPω3mediate
potent anti-inflammatory and insulin sensitizing effects through their
interaction with a membrane receptor named G-protein-coupled
receptor 120 (GPR120) [203,204]; they act at the gene expressional
level by binding to nuclear receptors, such as the peroxisome
proliferator activated receptors (PPARs) [205–207]; and they mod-
ulate physical and metabolic properties of membranes through their
incorporation into phospholipids and thereby impact on the forma-
tion of lipid rafts [134,208,209]. Important common denominators in
each of these interactions seem to be their anti-inflammatory and
metabolic effects, again illustrating the intimate connection between
the immune system and metabolism [50,51].
The modernization of food manufacturing, preservation processes
and food choices have dramatically altered the balance between
LCPω3 and LCPω6 in the Western diet, notably by increasing the
intake of LA from refined vegetable oils and a concomitant decrease in
the intake of LCPω3 from fish [210,211]. It is gaining acceptance that it
is not the amount of fat but the balance between the different types of
fatty acids that is important [211,212]. A high ω6/ω3 fatty acid ratio
has been demonstrated to have an inflammatory effect [86,212,213],
while a higher intake of LCPω3 in the form of EPA and DHA regulates
the production of inflammatory and resolving cytokines and de-
creases LA levels in both plasma phospholipids and cell membranes
[183,214]. The conversions of LA and ALA to AA and to EPA+DHA,
respectively, depend on the same enzymes in the desaturase and
elongase cascade, with Δ6-desaturase as a rate-limiting enzyme [215]
that functions twice in the biosynthesis of DHA [216]. Increased
consumption of ALA gives rise to an increased ALA/LA ratio and
EPA+DHA content in cell membranes that comes together with a
reduction of the AA content [216,217], and thereby influences thebalance between inflammation and its subsequent resolution (Fig. 6)
[218–220]. Conversely, a higher LA level in plasma phospholipids and
cell membranes emerges as a major factor responsible for incomplete
resoleomics reactions and the associated immune paralysis
[214,220,221] (Fig. 6), which is attributed to the competitive
inhibition of LA in the conversion of ALA to EPA and DHA and also
to the competition of LA in the incorporation of EPA and DHA into
cellular phospholipids [183,214,216].
LCPω3 and LCPω6 have distinct functions in the inflammatory
reaction and its resolution. In the first phase of the inflammatory
process, the pro-inflammatory eicosanoids leukotrienes-B4 and
prostagladins-E2 and D2 (PGE2 and PGD2) [222,223] are generated
by macrophages from their precursor AA with the help of the lipid-
oxidizing enzyme lipoxygenase-5 (LOX-5) and cyclo-oxygenase-2
(COX-2) [224–226]. At the same time, PGE2 and/or PGD2, although
initially pro-inflammatory, determine the switch to the next phase:
the resolution of the inflammation [227] via the so-called “eicosa-
noid-switch”. The production of the LOX-5 enzyme becomes limited,
while anti-inflammatory lipoxins (LXs) are produced from AA
through the activation of lipoxygenase-12 (LOX-12), lipoxygenase-
15 and acetylated COX-2 [228]. At the site of inflammation, LOX-12
produced by platelets converts LTA4 to LXA4 and LXB4. Along with AA,
both LOX-12 and−15 are involved in the biosynthesis of specialized
bioactive lipid mediators, coined resolvins, (neuro)protectins [135]
and maresins [229], which derive from EPA and DHA (Fig. 7)
[85,134,172]. Several studies have illustrated the involvement of
these lipid mediators in vascular inflammation and atherosclerosis
[85,228,230,231]. They possess potent anti-inflammatory and pro-
resolving actions that stimulate the resolution of acute inflammation
by reducing and/or limiting the production of a large proportion of
the pro-inflammatory cytokines produced by macrophages. Further-
more, LXA4, protectin D1 and resolvin D1 stimulate the phagocytic
activity of macrophages toward apoptotic cells and inhibit inflam-
matory cell recruitment [232,233], thereby protecting tissues from
excessive damage by the oxidative stress that comes along with
immune defense mechanisms and others. By their inhibitory actions
on the recruitment of inflammatory cells, they allow the resolution
phase to set in [234] and finish the inflammatory process with the
return to homeostasis [136,227].
Accordingly, LCPω3 given at doses of hundreds of milligrams to
grams per day, exhibits beneficial actions in many inflammatory
diseases [88,190,194,235,236]. For example, DHA has been shown to
suppress NFκB activation and COX-2 expression in a macrophage cell
line [168,237]. Different studies demonstrated the nutrigenetic
modulation of the 12/15-LOX by providing endogenous anti-inflam-
matory signals and protection during the progression of atherogen-
esis [231,238,239], which seem to be totally annulled in the presence
of Western diet induced hyperlipidemia. As some eicosanoids
regulate the production of inflammatory cytokines [85,134,135] an
LCPω3-induced decrease in pro-inflammatory eicosanoid production
might affect the production of pro-inflammatory cytokines. Equally
important is the observation that LCPω3 also modulate the activation
of transcription factors involved in the expression of inflammatory
genes (e.g., NFκB, phosphatidylinositol 3-kinase (PI3K)) [240]. Hence,
a high fish consumption, and especially fatty fish, rich in EPA and
DHA, seems of crucial importance in the primary and secondary
prevention of (Western) chronic diseases [241,242], although it
should be emphasized that fish is not a synonym of fish oil and also
that insufficient fish consumption is certainly not the only factor
involved in the pro-inflammatory Western lifestyle (Table 1).
6.2. Role of the antioxidant network
The largest contributor to mortality and morbidity worldwide is
age-related, non communicable disease, including cancer, CVD,
Fig. 6. Postulated LCPω6 and LCPω3 involvement in the inflammatory reaction in sepsis and its subsequent resolution. Sepsis causes a systemic inflammatory response giving rise to the
“systemic inflammatory response syndrome” (SIRS). The inflammatory response is followed by a compensatory anti-inflammatory response (CARS), characterized by aweakened host
defense and augmented susceptibility to secondary infections. An inflammatory response should not only be initiated, but also stopped to limit collateral damage produced by the
immune system and to prevent immune paralysis. LCPω6 (AA) are involved in the initiation of the inflammatory reaction, while LCPω3 (EPA and DHA) are involved in its resolution
(see also Figure 7). Panel A) A high LCPω6/LCPω3 ratio, e.g., low fish intake, intensifies the SIRS reaching a state of hyper-inflammation, while the CARS leads to a state of immune
paralysis. Panel B) A low LCPω6/LCPω3 ratio dampens both the SIRS and CARS, resulting in a more balanced immune response and preventing hyper-inflammation and immune-
paralysis. SIRS, systemic inflammatory response syndrome; CARS, compensatory anti-inflammatory response syndrome.
Adapted from Mayer et al. [220] with permission from Wolters Kluwer Health.
Fig. 7. Biosynthesis of inflammatory and resolving lipid mediators. AA is released frommembrane phospholipids by phospholipase A2 (PLA2) andmetabolized by COXs or 5-LO to form
inflammatory mediators, such as prostaglandins and leukotrienes. During the process of resolution, there is a “switch” from the biosynthesis of inflammatory mediators to the
formation of lipid derivatives with anti-inflammatory and pro-resolving properties, including lipoxins and 15-d-PGJ2. EPA and DHA are converted to potent anti-inflammatory and
pro-resolving lipid mediators like resolvins (E1 and D1) and protectins. ASA, acetylsalicylic acid, CYP450, cytochrome P450, COX-1, cyclo-oxygenasa-1, COX-2, cyclo-oxygenasa-2; 5-
LO, 5-lipo-oxygenase; 12-LO, 12-lipo-oxygenase; 15-LO, 15-lipo-oxygenase; PGE2, prostagladin-E2; PGD2, prostaglandin-D2; LTs, leukotrienes; 15d-PGJ2,15-deoxy-delta-12,14-
prostaglandin J2; 15-epi-LXA4, 15-epi-lipoxin A4; LXA4, lipoxin A4.
Adapted from González-Périz and Clària [243] with permission.
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are multi-factorial diseases with many pathophysiological mecha-
nisms, a common finding is oxidation-induced damage through
oxidative stress [245,246]. Appropriate antioxidant intake has been
proposed as a solution to counteract the deleterious effects of reactive
oxygen species (ROS; e.g., hydrogen peroxide, hypochlorite anion,
superoxide anion and hydroxyl radical), with substantial evidence
upholding the contention that: a diet rich in natural antioxidants
supports health [104,246], is associated with lower oxidative stress
and inflammation [77,103,140], and is therefore associated with
lower risk of cancer, CVD, Alzheimer's disease, cataracts, and some of
the functional declines associated with aging [247–251].
Molecular oxygen is essential to aerobic life and, at the same time,
an oxidizing agent, meaning that it can gain electrons from various
sources that thereby become “oxidized,”while oxygen itself becomes
“reduced” [252,253]. In general terms, an antioxidant is “anything
that can prevent or inhibit oxidation” and these are therefore needed
in all biological systems exposed to oxygen [252]. The emergence of
oxygenic photosynthesis and subsequent changes in atmospheric
environment [254] forced organisms to develop protective mecha-
nisms against oxygen's toxic effects [255]. Change is implicit to
evolution and evolution results in adaptation to change [256]. As a
result, many enzymatic reactions central to anoxic metabolism were
effectively replaced in aerobic organisms and antioxidant defense
mechanisms evolved [257,258]. The continuous exposure to free
radicals from a variety of sources led organisms to develop a series of
systems [259] acting as a balanced and coordinated network where
each one relies on the action of the others [260,261].
Oxidative stress occurs when there is a change in this balance in
favor of ROS [262] that may occur under several circumstances,
ranging frommalnutrition to disease [263,264]. Damage by oxidation
of lipids [262,265,266], nucleic acids and proteins changes the
structure and function of key cellular constituents resulting in the
activation of the NFκB pathway, promoting inflammation, mutation,
cell damage and even death [252,260,267] and is thereby believed to
underlie the deleterious changes in aging and age-related diseases
[102,244]. The prevention and/or inhibition of oxidation can be
achieved by several types of specialized antioxidant mechanisms
depicted in Table 2 [260]. Our antioxidant system is composed of two
networks (Fig. 8), namely, the antioxidant network of non-enzymatic
antioxidants that we obtain mostly via the diet [268], and the
antioxidant enzymes that we synthesize ourselves and that carry
metal ions for their appropriate functioning in ROS clearance.
Members of the non-enzymatic antioxidants are, e.g., ascorbic acid
(vitamin C), alpha-tocopherol (vitamin E), carotenoids, and the
polyphenols [269,270]. For instance, quercetin, one of the most
common flavonoids in the human diet, and resveratrol, a well-known
stilbenoid present mostly in berries and the skin of red grapes, have
demonstrated favorable effects on glucose metabolism by attenuating
TNFα-mediated inflammation and insulin resistance in primary
human adipocytes [271]. Typical examples of the antioxidantTable 2
Types of antioxidant action
Action Examples







ROS into harmless products
SOD, catalase,
glutathione peroxidase
Scavenging Sacrificial interaction with









Adapted from Benzie [260].enzymes are superoxide dismutase (SOD), glutathione peroxidase
(GPx) and catalase [252].
While the prevention of oxidative stress by enhancing the
antioxidant defense mechanisms may diminish the production of
inflammatory mediators and thereby slow aging and lower risk of
certain diseases [102,245,249], it should at the same time be
appreciated that ROS also exert essential metabolic and immune
functions. For example, oxidative phosphorylation is based on
electron transport [272], which renders free radicals” inevitable
byproducts of mitochondrial metabolism [273]. Mitochondrial oxi-
dants may function as signaling molecules in the communication
between themitochondria and the cytosol [273], while TNFα-induced
apoptosis may involve mitochondria-derived ROS [274]. The innate
immune system kills microbes by means of the respiratory burst
[275]. A certain level of ROS may also be essential to trigger
antioxidant responses [276]. Repeated exposure to sublethal stress
has been proposed to result in enhanced stress resistance and
increased survival rates, which in the dose–response curve is better
known as hormesis [277]. Intracellular ROS may stimulate gene
expression of antioxidant and immunoreactive proteins [278], while
SOD may become up-regulated in chronic exercise through the
binding of NFκB to the SOD promoter [279,280].
Consequently, certain antioxidants may inhibit mitochondrial
biogenesis, interfere with the hormetic effects of ROS [281,282] or
have other adverse effects. Effective prevention of ROS formation and
their removal may therefore upset energy metabolism, cell signaling
pathways and the immune system, and thereby paradoxically
increase the risk of chronic disease [283]. Moreover, any antioxidant
is also a potential pro-oxidant because in its scavenging action it gains
an extra electron that can initiate a new radical reaction when
transferred to an acceptor, either spontaneously or upon decompo-
sition [284,285]. Possibly through its prooxidant action or other
mechanisms [286], meta-analyses of studies with β-carotene dosages
above 20mg/day have shown increased risk of lung cancer in the total
population, smokers and asbestos workers; and of stomach cancer in
smokers and asbestos workers [287]. Analogously, oral antioxidants
to limit muscle damage following exercise training may be detri-
mental to health and performance [288], while β-carotene, vitamin A
and vitamin E supplements have been connected with higher risk of
all-cause mortality [289], although the outcome of the latter meta-
analysis has been contested [290]. Moreover, not all antioxidants are
created equal. Astaxanthin, a carotenoid from the land-water
ecosystem, does not appear to exhibit pro-oxidant properties [291]
when supplemented alone, even at high doses [292], and has been
shown to decrease oxidative stress and inflammation in various
circumstances [266,293].
Chronic inflammation results in the chronic generation of free
radicals, which may cause collateral damage and stimulate signaling
and transcription factors associated with chronic diseases [294,295].
The hypothesis that dietary antioxidants lower the risk of chronic
diseases has been developed from epidemiological studies consis-
tently showing that consumption of fruit and vegetables is strongly
associated with a reduced risk of these diseases [104,248,250].
Regular consumption of green tea [296] and red wine [103,297],
both rich in polyphenols, decreases DNA damage, and the same holds
for the kiwifruit [298] and watercress [299], both harboring high
amounts of carotenoids and vitamin C. On a calorie basis, fruits and
vegetables are not only richer in many vitamins and minerals, when
compared with cereals, meat or fish, but also in antioxidants [300].
These may collectively be responsible of the aforementioned
protection of fruits and vegetables in chronic diseases, including
CVD [248] and cancer [249]. Plants harbor similar defense mecha-
nisms as animals for protection against ROS [301]. Some of their
antioxidants are part of their arsenal of “secondary metabolites,”
defined as those organic compounds that are not directly involved in
Fig. 8. Antioxidant defense mechanisms. An overview of the antioxidant system present in the human body. Various types of antioxidant systems have developed through time,
reflecting different selection pressures. Different forms have developed for the same purpose, for example, SODs, peroxidases and GPx are important members of the antioxidant
enzyme capacity group. Tocopherols and ascorbic acid, as representatives of the antioxidant network, are manufactured only in plants, but are needed by animals. Ascorbic acid is an
essential antioxidant, but cannot be synthesized by Homo sapiens. In humans, therefore, antioxidant defense against toxic oxygen intermediates comprises an intricate network which
is heavily influenced by nutrition. GR, glutathione reductase; GSG, reduced glutathione; GSH-Px, glutathione peroxidase; GSSG, oxidized glutathione; GST, glutathione-S-transferase;
MSR, methionine sulphoxide reductase; PUFA, polyunsaturated fatty acids; S-AA, sulphur amino-acids; SH-proteins, sulphydryl proteins; SOD, superoxide dismutase; Fe Cu, transition
metal-catalysed oxidant damage to biomolecules.
Adapted from Strain [304] with permission from Cambridge University Press.
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survival and fecundity [302]. The plant secondary metabolites are
largely involved in the chemical defense against herbivores, microbes,
viruses and competing plants, in signaling and in nitrogen storage
[303]; and some (e.g., polyphenols, carotenoids) also serve functions
in the protection against ROS. The underlying metabolic pathways
towards secondary metabolites lead to a series of related compounds
that are usually composed of few major metabolites and several
minor components differing in the position of their functional groups
[303]. Animals consuming fruits and vegetables may employ these
plant secondary metabolite networks for their own purposes,
including maintenance of inflammatory/anti-inflammatory balance,
cancer chemoprevention and protection against ROS [303].
In view of the yet poorly understood complex antioxidant
networks composed of many compounds, it seems improbable to
find a single “magic bullet” to prevent and treat chronic diseases
associated with ROS. Protective effects of fruits and vegetables may
originate from their numerous phytochemicals working in concert
[305] and from many different mechanisms of action that are not
solely related to ROS. A purified phytochemical may not have the
same health benefit as that phytochemical present in whole foods or a
mixture of foods [250,306]. In biological systems, toxins may become
nutrients, while nutrients may become toxic in other situations [268],
for example when disbalanced with other nutrients. Rather than
translating our food into an assembly of nutrients where each has to
prove its health benefits by scientific means, the objective should be
to embrace a eucaloric diet that provides the adequate amount of
nutrients from whole foods to maintain our body homeostasis.“Adequacy” may in this sense be translated into causing an optimal
interaction between our diet (and our lifestyle in general) with our
genome, that is: nurture in balance with nature.
7. Evolutionary nutrition vs. randomized controlled trials
Coherence between lifestyle factors, including the composition of
our diet, is quite obvious from an evolutionary point of view. After all,
there was first an environment, and from this environment originated
a genome that was adapted to that environment: it is the substrate
(environment) that selects the organism, not vice versa. This is exactly
what Darwin meant with “conditions of existence,” as the most
important driving force in evolution. In other words, our only slowly
changing genome is indissolubly linked to a certain environment and
lifestyle. However, we have changed this environment since the
agricultural revolution and continue to do so with still increasing
paste. The resulting conflict does not generate acute toxicity, but acts
as an assassin in the long term. Probably, the conflict does not exert
much selection pressure either, because its associated mortality
occurs mainly after reproductive age.
To solve the conflict, it is virtually impossible to study all of the
introduced errors in our lifestyle (Table 1) in isolation, according to
the reigning paradigm of EBM [307]. EBM is widely confused with the
results of RCTs and preferably the meta-analysis thereof [308,309].
This paradigm, originally designed for objective evaluation of medical
treatments and drugs in particular, and named in nutrition research
“Evidence Based Nutrition”; is at present misused by food scientists
and Health and Nutrition advisory boards. In contrast to drugs, this
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single nutrients with meaningful outcomes [308]. For each nutrient,
we are dealing with poorly researched dose–response relationships,
multiple mechanisms of action, small effects causing pathology in the
long-term, numerous interactions, ethical limitations regarding the
choice of intervention and control groups, and the inability to patent
its outcomes [309]. The RCT criteria are moreover inconsistently
applied in the current development of nutritional recommendations.
For example, there is no RCT-supported evidence for the saturated fat
hypothesis [170], and also not for the trans fatty acids, while such an
approach is considered mandatory for the adjustment of the vitamin
D nutritional standards [310–312]. Incidentally, there was also no RCT
prior to the introduction of trans fatty acids showing that they could
be consumed without adverse effects on the long term. However,
there is an RCT on the effects of smoking cessation, which showed an
equal mortality among the quitters [313,314]. The meta-analyses of
RCTs studying the influence of LCP on brain development are negative
[315–318]. However, recommendations for their addition to infant
formulas have been issued [196], probably because nobody wants to
take chances with the brains of our offspring. By applying EBM in a
rigorousmanner and bymerely taking a view from the “precautionary
principle” (i.e., zero risk 4) this well meant concept has become a
burden in the nutritional science, that calls for replacement by
appropriate risk-cost-benefit analyses such as, e.g., performed for
vitamin D [319].
Our diet is composed of millions of substances that are part of a
biological network. In fact, we eat “biological systems” like a banana, a
fish or a piece of meat. There is a connection between the various
nutrients in these systems. In other words, there is a balance and an
interaction that is part of a living organism. This balance can be found
in the reconstruction of our Paleolithic diet, and various attempts for
this reconstruction have already been made [28,131,320–322].
Preliminary results of interventions with a Paleolithic diet are utterly
positive (for a review see [323]). For example, in an indeed
uncontrolled study with non-obese sedentary healthy subjects, an
eucaloric Paleolithic diet resulted within 10 days in beneficial effects
on three out of the four symptoms of the metabolic syndrome, i.e.
blood pressure, dyslipidemia and glucose homeostasis. The fourth
symptom, overweight/obesity, was deliberately not changed to
prevent the attribution of any beneficial changes to weight loss [324].8. Nurture, not nature
Less than 5% of our diseases can primarily be ascribed to heritable
genetic factors [325,326]. “Genomewide association studies” (GWAS)
will not make this figure change; not even if the number of patients
and controls are further increased. As it could have been predicted
from evolution, these GWAS identify only a few genes that are
associated with typically Western diseases. Moreover, the so far
identified genes merely convey low risks. In one of these disappoint-
ing GWAS, where 14,000 patients with sevenmajor typicallyWestern
diseases and 3.000 controls were studied, it was concluded that: “…
for any given trait, there will be few (if any) large effects, a handful of
modest effects and a substantial number of genes generating small or
very small increases in disease risk” [327]. The differences in genetic
susceptibility to environmental factors is widely confused with a4 The precautionary principle is a moral and political principle stating that, if an
intervention or policymay cause serious or irreversible damage to society or the
environment, the burden of proof lies with theproponents of the intervention or the
measure if there is no scientific consensus on the future damage. The precautionary
principle is particularly applicable in health care and environment; in both cases we
deal with complex systems in which interventions result in unpredictable effects
(source: Wikipedia).primary genetic origin ofWestern disease. Environmental factorsmay
mimic genetic heritability, especially when the exposure has become
widespread. As clearly explained by Rose [328]: "If everyone smoked
20 cigarettes a day, then clinical, case–control and cohort studies alike
would lead us to conclude that lung cancer was a genetic disease; and
in one sense that would be true, since if everyone is exposed to the
necessary agent, then the distribution of cases is wholly determined
by individual susceptibility”. In other words: “disease susceptibility
genes” is a misnomer from an evolutionary point of view.
Most of the currently demonstrated polymorphisms associated
with typically Western diseases already existed when Homo sapiens
emerged about 160,000 years ago in East-Africa. After all, the largest
inter-individual genetic variation can be found between individuals
belonging to a single population (93–95% of the total genetic
variation), and only little genetic variation is on the account of
differences between populations belonging to a single race (2%) and
between the 5 races (3–5%) [329]. The allele that, according to current
knowledge, is linked with the highest penetrance of type 2 diabetes
mellitus in the general population conveys 46% higher relative risk
(RR=1.46) [330]. In contrast, a womanwith a bodymass index of 35+
kg/m2 has a one hundred-fold higher risk (RR=100) of diabetes
mellitus type 2 [331], which translates into a 9,900% higher relative
risk. “Genetic” diseases with relative risks below 1.5 have no practical
value in Public Health. They are only important to our understanding
of the etiology of the concerning disease and for drug development
[326], which is part of Health Care.
Between 70 and 90% of the cases of type 2 diabetes mellitus, CVD
and colon cancer can be prevented by paying more attention to
nutrition, smoking, overweight and lack of physical activity [325].
Hemminki et al. [326] stated that “if the Western population was to
live in the same conditions as the populations of developing countries,
the risk of cancer would decrease by 90%, provided that viral
infections and mycotoxin exposures could be avoided”. The popular
counter argument that people in developing countries have shorter
life spans is not valid. The reason that we live longer in Western
societies, is mainly due to the strong reduction of infectious diseases
(particularly in childhood), famine and violence [332,333], and is also
partly on the account of Health Care. However, together with our
increasing life expectancy, there is a decrease in the number of years
without chronic disease [334].
9. Conclusions
It has become clear that most, if not all, typically Western chronic
illnesses find their primary cause in an unhealthy lifestyle and that
systemic low grade inflammation is a common denominator. From an
evolutionary point of view, the current conflict between environment
and our Paleolithic genome traces back to our brain growth and the
ensuing intimate relationship between inflammation and metabo-
lism. The present disbalance between inflammatory and anti-
inflammatory stimuli does not originate from a single cause and can
consequently also not be solved by a single “magic bullet”. Resolution
of the conflict between environment and our ancient genome might
be the only effective manner to arrive at “healthy aging” and to
achieve this objective we might have to return to the lifestyle of the
Paleolithic era according to the culture of the 21st century [16,322].
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